BSD Medical has reported the positive study results of its BSD-2000 hyperthermia system, which is used to treat cancer.

The BSD-2000 hyperthermia system delivers localised therapeutic heating by applying radiofrequency energy to the tumour.

The open-label comparative cohort study enrolled 60 patients with locally advanced and unresectable pancreatic cancer, and showed that patients treated using the hyperthermia system had an improved survival rate with no increase in toxicity.

The company is currently conducting a clinical study to evaluate the safety and efficacy of hyperthermia using the BSD-2000 combined with radiotherapy for the treatment of patients suffering from locally advanced, persistent or recurrent deep tumours of the pelvis.

BSD has also applied for a humanitarian device exemption approval for the device.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.